ArticleDrug design, development and therapy2017

Efficacy of the dual PI3K and mTOR inhibitor NVP-BEZ235 in combination with imatinib mesylate against chronic myelogenous leukemia cell lines.

Pengliang Xin et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.